NR1D2 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-07 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Inositol nicotinate, also known as inositol hexanicotinate or inositol hexaniacinate, is a compound of niacin (vitamin B3) and inositol. It is marketed in the United States as a "no-flush" form of niacin in dietary supplements. When ingested, inositol nicotinate breaks down into inositol and niacin. The niacin component helps widen blood vessels (vasodilation), lowers blood lipid levels (including cholesterol), and inhibits a protein involved in blood clotting. Inositol nicotinate is used to treat blood circulation problems, including: Raynaud's phenomenon Intermittent claudication Some research shows it can improve symptoms of Raynaud's phenomenon over several weeks. However, its effectiveness in treating other conditions like: High cholesterol High blood pressure Leg pain during exercise (due to poor circulation) remains unclear, with studies producing mixed results. Other proposed uses, such as for: Migraines Psoriasis Restless legs syndrome have insufficient supporting evidence. Inositol nicotinate is generally safe when taken by mouth, but possible side effects include:
Roentgenium has no stable or naturally occurring isotopes. Several radioactive isotopes have been synthesized in the laboratory, either by fusion of the nuclei of lighter elements or as intermediate decay products of heavier elements. Nine different isotopes of roentgenium have been reported with atomic masses 272, 274, 278–283, and 286 (283 and 286 unconfirmed), two of which, roentgenium-272 and roentgenium-274, have known but unconfirmed metastable states. All of these decay through alpha decay or spontaneous fission, though 280Rg may also have an electron capture branch.
=== Rehabituation to dairy products === Regular consumption of dairy foods containing lactose can promote a colonic bacteria adaptation, enhancing a favorable microbiome, which allows people with primary lactase deficiency to diminish their intolerance and to consume more dairy foods. The way to induce tolerance is based on progressive exposure, consuming smaller amounts frequently, distributed throughout the day. Lactose intolerance can also be managed by ingesting live yogurt cultures containing lactobacilli that are able to digest the lactose in other dairy products.
== External links == Nonlinear Fracture Mechanics Notes by Prof. John Hutchinson, Harvard University Notes on Fracture of Thin Films and Multilayers by Prof. John Hutchinson, Harvard University Fracture Mechanics by Piet Schreurs, TU Eindhoven, The Netherlands
Sources: en.wikipedia.org
Strength training typically incorporates strengthening the muscles of the body. This means that the tension of the muscle when at rest will ordinarily be increased. This also influences the length of the muscle in a relationship known as length-tension. This length-tension of the muscle influences the standard position of the joints it connects to via the tendons. If it is too tight or too loose then the respective joints risk being pulled or falling out of their optimum position which is known as being centrated (centered). The optimum positioning of a joint is gained and maintained by the muscles which influence it, including the agonists and antagonists, being of the correct length-tension and in the appropriate balance of strength with each other. In turn, the optimum joint position means that the muscles length-tension is regulated more efficiently with greater levels of control. Due to this reciprocal relationship between the muscles and joints, strength training programmes seek to ensure that the muscles are not strengthened in an excessive and disharmonious way which will lead to poor joint alignment (decentration). Where poor joint alignment does occur the amount of force the muscles can apply is reduced, movement control (agility) is reduced, and injury risk is increased especially in regard to wear and tear injuries. Forms of exercise which seek to specifically improve joint alignment, and thereby increase joint stability and flexibility, include those which emphasise balance and proprioception e.g.
Parliamentary elections were held in Portugal on 29 January 1922. The Democratic Party emerged as the largest in Parliament, winning 74 of the 163 seats in the House of Representatives and 37 of the 70 seats in the Senate.
SO3 + H2O → H2SO4 (ΔfH = −200 kJ/mol) Gaseous sulfur trioxide fumes profusely even in a relatively dry atmosphere owing to formation of a sulfuric acid mist. SO3 is aggressively hygroscopic. The heat of hydration is sufficient that mixtures of SO3 and wood or cotton can ignite. In such cases, SO3 dehydrates these carbohydrates. Akin to the behavior of H2O, hydrogen fluoride adds to give fluorosulfuric acid:
=== Essential Bases === However, 23S rRNA positions (G2252, A2451, U2506, and U2585) have a significant function for tRNA binding in the P site of the large ribosomal subunit. These modification nucleotides in site P can inhibit peptidyl-tRNA from binding. U2555 modification can also intervene with transferring peptidyl-tRNA to puromycin. Furthermore, the chemical modification of half of these positions G2251, G2253, A2439, and U2584 can not prevent the tRNA binding. Peptidyl-tRNA of 50S subunits which binds to the P site preserve eight positions of 23S rRNA from chemical modification. On the other hand, mutation in 23S rRNA can also have impacts on cell growth. Mutations A1912G, A1919G and Ψ1917C have a powerful growth phenotype and they prevent translation while mutation A1916G has a simple growth phenotype and it leads to defect in the 50S subunits.
During his mayoralty, Sanders called himself a socialist and was described as such in the press. During his first term, his supporters, including the first Citizens Party city councilor Terry Bouricius, formed the Progressive Coalition, the forerunner of the Vermont Progressive Party. The Progressives never held more than six seats on the 13-member city council, but they had enough to keep the council from overriding Sanders's vetoes. Under his leadership, Burlington balanced its city budget; attracted a minor league baseball team, the Vermont Reds, then the Double-A affiliate of the Cincinnati Reds; became the first US city to fund community-trust housing; and successfully sued the local cable television franchise, thereby winning reduced rates for customers. Sanders led downtown revitalization projects, including the improvement of Burlington's Lake Champlain waterfront. In 1981, he campaigned against the unpopular plans by Burlington developer Tony Pomerleau to convert the then-industrial waterfront property owned by the Central Vermont Railway into expensive condominiums, hotels, and offices. He ran under the slogan "Burlington is not for sale" and successfully supported a plan that redeveloped the waterfront area into a mixed-use district featuring housing, parks, and public spaces. Sanders was a consistent critic of US foreign policy in Latin America throughout the 1980s. In 1985, Burlington City Hall hosted a foreign policy speech by Noam Chomsky.
Sources: en.wikipedia.org
== History == Translationally controlled tumor protein was first discovered in 1989 as a cDNA sequence obtained from a human mammary carcinoma cDNA library with proves derived from the translationally controlled, growth-related mouse tumor protein TCTP. TCTP was originally described as a growth related protein of tumor cells. Its mRNA accumulates in translationally repressed postpolysomal mRNP-complexes. Research in 1997 shown that TCTP is not a tumor- or tissue-specific protein, but is expressed ubiquitously from plants to mammals. Later studies show TCTP involvement in a protozoan Trypanosoma brucei.
Back in the night, James meets with Grace as per her instructions and she asks James to forsake his Shadowhunter blood, run away, and marry her. It’s the only way she can escape her cruel mother. James silently considers it but decides there’s no way he can forsake his family, friends, or parabatai. Grace is angry at his declaration, but she’s cut short when demons attack them. Lucie, Christopher, Matthew, Thomas, Cordelia and Alastair come to their aid. The strongest demon recognizes James and asks why James is fighting against the creatures who worship his own grandfather. The demon calls Tessa’s demon father a prince of hell, which is a fallen angel as powerful as Raziel. James is shocked at the revelation. He lets the remaining demons go in the name of his grandfather as long as they go back to their own dimension. They will do so as long as no one present tells any other Shadowhunters about what transpired at the waterfront. After they’re gone, Tatiana pulls up in her carriage searching for Grace. James begs Grace to come to the Institute with him. His father will grant her safe haven. Tatiana promises to produce evidence to ruin Grace's reputation if she doesn’t come home with her. Ragnor visits the teenagers-sans Cordelia and Alastair, and gives them a lead - Emmanuel Gast, who he thought might be able to dredge up information. Shocking news arrives when Barbara Lightwood is pronounced dead. At the Carstairs manor in Cornwall Gardens, Charles visits late at night.
==== United States ==== JRT is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
=== Other anabolic agents === Clenbuterol – a beta-agonist; anabolic ability dubious Selective androgen receptor modulators (SARMs) Tibolone – a synthetic steroid Zeranol – a nonsteroidal estrogen Zilpaterol – a beta2-agnoist; anabolic ability dubious
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.